Skip to main content

Table 1 Demographic and baseline patient characteristics

From: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

Characteristics

No of patients (n = 14)

Percent

Gender

  

 Male

6

42.9

 Female

8

57.1

Age, median (range)/years

56.5 (14-81)

Performance status (ECOG)

 

 0–1

13

92.9

 2

1

7.1

Stage at diagnosis (Masaoka-Koga)

  

 IVa

3

21.4

 IVb

8

57.1

 Recurrence

3

21.4

Metastatic sites (overlapped)

  

 Lung

6

 

 Liver

2

 

 Lymph nodes

5

 

 Pleura

5

 

 Bone

3

 

 Brain

1

 

Histologic subtype

  

 Squamous cell carcinoma

12

85.7

 Lymphoepithelioma-like carcinoma

1

7.1

 Undifferentiated carcinoma

1

7.1

Previous chemotherapy

  

 ADOC

3

 

 Cisplatin-irinotecan

9

 

 Cisplatin-gemcitabine

1

 

 Carboplatin-gemcitabine

1

 
  1. No number, ADOC cisplatin, adriamycin, vincristine, and cyclophosphamide